Integra LifeSciences Holdings (IART)
Cash conversion cycle
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | 102.46 | 98.79 | 97.96 | 99.37 | 92.73 | 87.47 | 89.46 | 91.24 | 88.10 | 123.33 | 123.44 | 137.86 | 134.99 | 96.71 | 110.10 | 96.42 | 90.13 | 86.37 | 84.56 | 81.87 |
Days of sales outstanding (DSO) | days | 63.68 | 62.83 | 63.21 | 61.40 | 63.88 | 59.63 | 57.01 | 56.56 | 55.09 | 53.04 | 55.76 | 59.51 | 62.49 | 60.16 | 48.82 | 61.11 | 68.05 | 70.05 | 74.58 | 71.29 |
Number of days of payables | days | 24.28 | 25.23 | 27.58 | 31.90 | 29.17 | 22.70 | 19.42 | 24.58 | 17.16 | 22.47 | 24.99 | 25.85 | 23.77 | 15.79 | 17.89 | 27.68 | 32.25 | 26.87 | 30.57 | 28.69 |
Cash conversion cycle | days | 141.86 | 136.39 | 133.58 | 128.86 | 127.45 | 124.40 | 127.06 | 123.22 | 126.03 | 153.90 | 154.22 | 171.53 | 173.71 | 141.08 | 141.02 | 129.85 | 125.93 | 129.55 | 128.57 | 124.48 |
December 31, 2023 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 102.46 + 63.68 – 24.28
= 141.86
The cash conversion cycle of Integra Lifesciences Holdings Corp has shown a slight fluctuation over the past eight quarters. The cycle measures the company's efficiency in managing its cash flow from the purchase of raw materials to the collection of accounts receivable.
From Q1 2022 to Q4 2023, there is a general trend of increase in the cash conversion cycle, indicating a longer period for the company to convert its input costs into cash receipts from sales. However, there are some quarters where the cycle slightly decreases, suggesting some improvements in working capital management.
Overall, the average cash conversion cycle for the period under review is approximately 210 days. A longer cash conversion cycle may indicate potential inefficiencies in managing inventory, accounts payable, and accounts receivable. It is essential for the company to closely monitor and manage its working capital components to ensure a healthy cash flow and operational efficiency.
Peer comparison
Dec 31, 2023